Where does Ambrx, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Ambrx, Inc. ranks #6,308 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Ambrx, Inc. hold?

Ambrx, Inc. holds 53 US utility patents granted between 2015 and 2025, spanning 15 technology areas.

What is Ambrx, Inc.'s Innovation Score?

Ambrx, Inc. has an Innovation Score of 46.1 out of 100 (top 22% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Ambrx, Inc. focus on?

Ambrx, Inc.'s top technology area is C07K (Peptides) with 45 patents, ranking #207 of 3,615 assignees active in that subclass. Grants appear in 15 CPC subclasses total.

Is Ambrx, Inc.'s patent grant rate increasing or decreasing?

Ambrx, Inc.'s recent grant velocity is -21% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Ambrx, Inc.'s patents?

Ambrx, Inc.'s patents average 15.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Ambrx, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Ambrx, Inc.

USPTO PatentsView assignee record - 53 granted patents across 15 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Ambrx ranks #6,308 of 49,997 tracked US assignees by granted-patent volume, with 53 patents across 15 technology areas.

#6,308
of 49,997 US assignees by volume: Top 22%
by Innovation Score (46.1/100): 15.8
avg claims per patent: -21%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R6308 · US Corporation #6,308 · 53 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 53 grants
UPPER-Q #6,308/49,997
PHOTO-FINISH Acergy France SAS
CPC-FOCUS C07K · 15 areas
INNOV-PAR 46.1/100
CLAIMS-RICH 15.8 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -21% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Acergy France SAS (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Ambrx’s 46.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.8 pts (30%) Velocity 9.1 pts (20%) Breadth 13.7 pts (30%) Claim depth 9.5 pts (21%)

Qualcomm Incorporated · highest

85
Ambrx · this assignee

46
J SCHMALZ · near

46
Kba-notasys · near

46
StubHub · near

46
Textron · near

46
3D Lighting… · lowest

7

What this shows Ambrx's Innovation Score is 46.1/100 (top 22% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Ambrx?

Each dot is one of Ambrx’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Ambrx’s own 15.8 claims/patent is ABOVE the 15.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Ambrx vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Ambrx's grants concentrate

Ambrx, Inc. is a focused PatentsView assignee: 15 CPC subclasses with 84.9% of grants classified under C07K (Peptides). Peak complete grant year is 2015 (8 grants) versus a trough of 3 in 2021. By volume, Ambrx sits between Acergy France SAS and Board OF Trustees OF THE University OF Illinois.

Ambrx's three-year grant acceleration

Ambrx, Inc. shows 15 grants in 2022–2024 against only 11 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Acergy France SAS

53
Advansix Resins &…

53
Ambiq Micro

53
Alitheon

53
BD Kiestra B V

53
Bloomy Lotus

53
Board OF Regents…

53
Board OF Trustees…

53
Ambrx ◀

53

What this shows Ambrx holds 53 patents at rank #6,308, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Ambrx

By rank, the assignees closest to #6,308 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Ambrx's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Ambrx, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Ambrx ranks #207 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (46 here).

Kba-notasys SA 46 StubHub, Inc. 46 Textron Inc. 46 J.SCHMALZ GMBH 46

Similar claim depth

Nearest assignees by average claims per patent (15.8 here).

Hytto PTE. Ltd. 15.8 avg MOR Research Applications Ltd. 15.8 avg THE Hillman Group, Inc. 15.8 avg Abbott Laboratories 15.8 avg

Ambrx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 22% higher than 78% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Ambrx, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	8	15.1%
2016	4	7.5%
2017	6	11.3%
2018	6	11.3%
2019	4	7.5%
2020	4	7.5%
2021	3	5.7%
2022	5	9.4%
2023	6	11.3%
2024	4	7.5%
2025partial year	3	5.7%

Which technologies does Ambrx, Inc. patent most?

C07K - Peptides 45

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 44

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 39

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 17

Y02A - Technologies FOR Adaptation TO Climate Change 11

C07D - Heterocyclic Compounds 4

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 3

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

C07C - Acyclic OR Carbocyclic Compounds 2

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 2

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 2

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

C12Y - Enzymes 1

C08F - Macromolecular Compounds Obtained BY Reactions Only Involving Carbon-to-carbon Unsaturated Bonds 1

Top 15 of 15 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Ambrx, Inc.'s patent record in context - here's where to go next.

Ambrx, Inc.'s lead technology class is C07K (Peptides), 84.9% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #6,308 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Ambrx, Inc. against Acergy France SAS, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 46.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.